Fig. 1: Selinexor and gemcitabine preclinical synergy evaluation. | Nature Communications

Fig. 1: Selinexor and gemcitabine preclinical synergy evaluation.

From: Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma study

Fig. 1: Selinexor and gemcitabine preclinical synergy evaluation.The alternative text for this image may have been generated using AI.

A Isobologram displays the IC50 concentration of selinexor on the X-axis and the IC50 concentration of gemcitabine on the Y-axis. The combination point represents the IC50 values for the combined treatment: the X value indicates the IC50 for selinexor in the combination, and the Y value indicates the IC50 for gemcitabine in the combination. A combination-point below the line connecting the single-agent IC50s indicates synergy, on the line indicates an additive effect, and above the line indicates antagonism (experimental replicas on different days: n = 3 with 3 technical replicas). B Apoptosis was assessed by Annexin V-FITC/propidium iodide (PI) flow cytometry assay. Quantification of necrotic and apoptotic cell populations is presented as percentages of total LMS (CP0024, SK-UT-1, AA and IEC005), osteosarcoma (MG-63, U2OS and SAOS-2), and MPNST (ICP060, S462, sNF96.2 and 88-14) cells after 72-h treatment with either 1 µM selinexor, 1.5 nM gemcitabine, or the combination of both (experimental replicas on different days: n = 3). Bar plots represent mean values with standard deviations; dots indicate individual samples. For statistical analysis, two-tailed t-tests were conducted. *p values: CP0024 p: 0.049, SK-UT-1 p: 0.016, ICP060 p: 0.017, S462 p: 0.011.

Back to article page